Palivizumab (Synagis®)

Onderzoeksoutput: Hoofdstuk in Boek/Rapport/CongresprocedureHoofdstukpeer review

2 Citaten (Scopus)

Samenvatting

Palivizumab is a humanized monoclonal antibody directed against the respiratory syncytial virus (RSV) F glycoprotein. It is delivered by monthly intramuscular injection during the RSV season. It is indicated for prematurely born infants up to gestational age 35 weeks and children with congenital heart disease to prevent hospital admission by RSV infection. Palivizumab has been shown to prevent recurrent wheeze in the first year of life in otherwise healthy preterm gestational age 33-35 weeks.

Originele taal-2Engels
TitelApproved Therapeutic Antibodies and in vivo Diagnostics
UitgeverijWiley-Blackwell
Pagina's1825-1854
Aantal pagina's30
Volume4-4
ISBN van elektronische versie9783527682423
ISBN van geprinte versie9783527329373
DOI's
StatusGepubliceerd - 3 dec. 2014
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Palivizumab (Synagis®)'. Samen vormen ze een unieke vingerafdruk.

Citeer dit